Personal Statement:
The critical analysis of new products before approval is essential to prevent the hurried release of new and unproven therapeutic and diagnostic drugs and devices.  As a neuro-oncologist, I am aware of the danger that anything less than critical scientific examination of new technologies is a disservice to the cancer community. Without this kind of protection, vulnerable patients who are grasping at hope to be cured of a dreaded condition can derive no benefit or, worse, be harmed. The drug and device industries often rush to promote promising but unproven products with resultant harm that outweighs any benefit.  CTAF in this regard is a gate-keeper committed to patient safety and benefit.

Current Occupation:
Consultant on neuroscience institutes with an emphasis on neuro-oncology

Education:
MD, Residency and Faculty at Tulane University
Masters in Health Administration, University of Colorado

Professional Affiliations:
Institute for the Future, Palo Alto, CA
Health Technology Center, San Francisco
American Association of Neurological Surgery
Congress of Neurosurgery
American Academy of Neurosurgery
American Society of Clinical Oncology
National Cancer Advisory Board, NCI